Vera Therapeutics
VERA
219 hedge funds and large institutions have $3.34B invested in Vera Therapeutics in 2026 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 100 increasing their positions, 66 reducing their positions, and 37 closing their positions.
55% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $8.18M
52% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 66
14% more capital invested
Capital invested by funds: $2.92B → $3.34B (+$422M)
7.34% more ownership
Funds ownership: 101.23% → 108.57% (+7.3%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
4% less funds holding
Funds holding: 229 → 219 (-10)
19% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$90.6M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$82M |
| 3 |
State Street
Boston,
Massachusetts
|
+$29.3M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$27.7M |
| 5 |
BlackRock
New York
|
+$24.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$55M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$43.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$20.9M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$18.9M |
| 5 |
FTM
First Turn Management
Del Mar,
California
|
-$17M |
VERA Hedge Fund Activity: Q2 2026 in Review
219 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q2 2026, worth a combined $3.34B — up 14% from $2.92B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of VERA and 30 opened new positions — a net loss of 7 holders — while 66 trimmed existing stakes and 100 added.
The largest buyer was Morgan Stanley, adding an estimated $90.6M. The largest seller was Vestal Point Capital, exiting entirely with an estimated $55M sold.
- 219 institutional investors held Vera Therapeutics (VERA) as of Q2 2026, down from 229 in Q1 2026.
- Funds reported $3.34B of Vera Therapeutics stock for Q2 2026, up 14% quarter-over-quarter.
- 30 funds opened new Vera Therapeutics positions in Q2 2026 and 37 closed out, a net change of -7 holders.
- The largest Vera Therapeutics buyer in Q2 2026 was Morgan Stanley, an estimated $90.6M added.
- The largest Vera Therapeutics seller in Q2 2026 was Vestal Point Capital, an estimated $55M sold.
Based on aggregated 13F filings for Q2 2026.